SYS6043

· Conjupro Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SYS6043, covering 2026-02-17 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors [Phase 1]